Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis

Author： Josse Robert Khan Aliya Ngui Daniel Shapiro Marla

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.29, Iss.3, 2013-03, pp. : 205-216

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical use of denosumab for the treatment for postmenopausal osteoporosis

By Lewiecki E. Michael

Current Medical Research and Opinion, Vol. 26, Iss. 12, 2010-12 ,pp. : 2807-2812

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

By Jönsson B. Ström O. Eisman J. Papaioannou A. Siris E. Tosteson A. Kanis J.

Osteoporosis International, Vol. 22, Iss. 3, 2011-03 ,pp. : 967-982

Springer Publishing Company

Access to resources Recommend Favorite

Denosumab-induced Normocalcemic Hyperparathyroidism in a Woman with Postmenopausal Osteoporosis and Normal Renal Function

Current Drug Safety, Vol. 13, Iss. 3, 2018-11 ,pp. : 214-216

Bentham Science Publishers

Access to resources Recommend Favorite

THE ONSET OF POSTMENOPAUSAL OSTEOPOROSIS AS STUDIED BY A NEW TECHNIQUE

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 14, Iss. 9, 1966-09 ,pp. : 930-934

John Wiley & Sons Inc

Access to resources Recommend Favorite

Denosumab: a promising drug for the prevention and treatment of osteoporosis

By Lewiecki E Michael

Women's Health, Vol. 2, Iss. 4, 2006-07 ,pp. : 517-525

Future Medicine

Access to resources Recommend Favorite